Clinical trial
Study Evaluating CMD-193 in Advanced Malignant Solid Tumors
NCT00161642 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00161642 |
|---|---|
| Title | Study Evaluating CMD-193 in Advanced Malignant Solid Tumors |
| Official title | A Phase 1 Dose Escalation Study of CMD-193 in Subjects With Advanced Malignant Tumors. |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | CMD-193 |
| Enrollment | 54 |
| Start date | Nov 1, 2004 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Sep 12, 2005 |
| Last update posted | Sep 10, 2009 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: